Follicum AB reports top-line data from First-in-Man Scalp Study with FOL-005 against hair loss
Follicum featured in the June issue of The New Yorker: “Is the Age-Old Quest for a Baldness Cure Reaching Its End?”
Follicum collaborates with proDERM for the upcoming Phase IIa clinical trial on patients with hair loss
Follicum comments on patent notice for diabetes candidate - BioStock
Is the Age-Old Quest for a Baldness Cure Reaching Its End? | The New Yorker
Follicum receives grant of a patent in the U.S. for extended protection of the product candidate FOL-005
Follicum strengthens its clinical expertise in diabetes as novel peptide candidate approaches clinic - establishes Scientific Ad
Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies
Female alopecia – new solutions on the horizon - BioStock
Follicum applies for extended patent for its topical formulation - BioStock
Clinical progress of Follicum's lead candidate FOL-005 for hair growth presented at the world's largest hair conference
Female alopecia – new solutions on the horizon - BioStock
Follicum finalises patient recruitment in hair growth study - BioStock
Follicum successfully completes toxicology studies for upcoming FOL-005 Phase IIa clinical trial in patients with hair loss
Follicum appoints new CEO and establishes new role as Chief Scientific Officer
glucotox eng - Follicum
Follicum files patent application for new topical formulation of FOL-005 for hair loss
Market notice 189/21 – Follicum is moved to the Observation List
Follicum receives LUDC post-doc funding for novel diabetes peptide mode of action research
Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres
150/19 – Information regarding the rights issue from Follicum AB
Follicum takes a step closer to phase III entering 2021 - BioStock
Follicum AB reports that all patients have completed treatment with FOL-005 in the Phase II study against hair loss
Endpoints News article about Follicum
Market Notice 11/22 – Follicum AB will be delisted after close of the market on February 3, 2022
